Carlos Becerra, MD
Medical Oncology · Dallas, TXNPI 1235171281
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $57,327 of the $93,946 with a category attached, or 61.0%. 26 manufacturers reported payments, led by Ipsen Biopharmaceuticals, Inc at 56.8% of the total.
Across 158 payments — averaging $594.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Ipsen Biopharmaceuticals, Inc$53K
- Taiho Oncology, Inc.$10K
- E.r. Squibb & Sons, L.L.C.$10K
- Novartis$5K
- Legend Biotech USA Inc.$3K
- Deciphera Pharmaceuticals Inc.$2K
- plus $11K from 20 others
Across 389 payments — averaging $6081.40 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- E.r. Squibb & Sons, L.L.C.$550K
- Gilead$315K
- Blueprint Medicines Corporation$261K
- Merck$255K
- Amgen$232K
- Novartis$117K
- plus $635K from 19 others
What the payments were for
- Consulting fees$57,32761%
- Speaking & faculty fees$23,98026%
- Travel & lodging$8,9159%
- Food & beverage$3,6244%
- Education$990%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Ipsen Biopharmaceuticals, Inc | 46 | $53,333 |
| Taiho Oncology, Inc. | 10 | $9,833 |
| E.r. Squibb & Sons, L.L.C. | 12 | $9,798 |
| Novartis | 5 | $4,669 |
| Legend Biotech USA Inc. | 2 | $3,491 |
| Deciphera Pharmaceuticals Inc. | 1 | $2,200 |
| F. Hoffmann-la Roche AG | 2 | $2,130 |
| AstraZeneca | 1 | $1,943 |
| Amgen | 1 | $1,500 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $1,238 |
| AbbVie | 50 | $1,117 |
| Novocure Inc. | 1 | $1,100 |
| Kyowa Kirin Co., Ltd | 5 | $959 |
| Seagen Inc. | 1 | $137 |
| Daiichi Sankyo Inc. | 4 | $110 |
| Jazz Pharmaceuticals Inc. | 1 | $76 |
| Siemens Medical Solutions USA, Inc. | 5 | $75 |
| Array Biopharma Inc | 2 | $35 |
| Merck | 1 | $33 |
| Galvanize Therapeutics, Inc | 1 | $32 |
| Teva Pharmaceuticals USA, Inc. | 1 | $29 |
| Bayer | 1 | $25 |
| Coherus Oncology, Inc. | 1 | $25 |
| Rigel Pharmaceuticals, Inc. | 1 | $22 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $20 |
| Kyowa Kirin, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$93,946 in reported general payments places this provider in the 85th percentile of 495 medical oncology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dexamethasone | 62 | $1,132 |
| Imatinib Mesylate | 12 | $1,049 |
| Ondansetron Hcl | 72 | $1,008 |
| LoperamideLoperamide Hcl | 35 | $855 |
| Olanzapine | 43 | $617 |
| Prochlorperazine Maleate | 66 | $562 |
| Lidocaine-PrilocaineLidocaine/Prilocaine | 41 | $431 |
| Ondansetron OdtOndansetron | 16 | $197 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Dallas
- Moshe LevyDallas$5.1M
- Andrew WhiteleyDallas$1.7M
- Eric NadlerDallas$1.6M
- Joyce O'ShaughnessyDallas$1.3M
- Ronan KellyDallas$1.1M
- Thomas HutsonDallas$944K
- Heather McArthurDallas$314K
- Tian ZhangDallas$286K
- Micah BurchDallas$221K
- David JohnsonDallas$212K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.